{"name":"AGO Study Group","slug":"ago-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"3 cycles of standard chemotherapy","genericName":"3 cycles of standard chemotherapy","slug":"3-cycles-of-standard-chemotherapy","indication":"Other","status":"phase_1"},{"name":"ACA 125","genericName":"ACA 125","slug":"aca-125","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TC","genericName":"TC","slug":"tc","indication":"Breast cancer (adjuvant and neoadjuvant treatment)","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"TCG","genericName":"TCG","slug":"tcg","indication":"Hypertriglyceridemia","status":"marketed"}]}],"pipeline":[{"name":"TC","genericName":"TC","slug":"tc","phase":"marketed","mechanism":"TC is a chemotherapy regimen combining docetaxel and cyclophosphamide, which work synergistically to inhibit cell division and induce apoptosis in cancer cells.","indications":["Breast cancer (adjuvant and neoadjuvant treatment)"],"catalyst":""},{"name":"3 cycles of standard chemotherapy","genericName":"3 cycles of standard chemotherapy","slug":"3-cycles-of-standard-chemotherapy","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACA 125","genericName":"ACA 125","slug":"aca-125","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"TCG","genericName":"TCG","slug":"tcg","phase":"marketed","mechanism":"TCG works by inhibiting the activity of certain enzymes in the body.","indications":["Hypertriglyceridemia","Mixed dyslipidemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBYX2ZqSHllVmU2WFBQcmE3akwtMnZpRkZ5MHVXTm1hYkVScjdBYzluZzJRaEF2NU9ZdDNRemk5dWZrMmlBMDNjNUE2M0VzRXItWnIxT01ZRHNELW9qSHlJQXA0Yk12V3dQVlE?oc=5","date":"2026-04-01","type":"pipeline","source":"Yahoo! Finance Canada","summary":"InnoCan Pharma Corp. R (IP40.DU) Latest Press Releases & Corporate News - Yahoo! Finance Canada","headline":"InnoCan Pharma Corp. R (IP40.DU) Latest Press Releases & Corporate News - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOS2h2WXhoSG1kN3Nwa0Q1azlobmVYMktPT2R2NjBaZ2VXN1lIZnlRNUZoZV9zRFhNazNlNXRtR1kzamYzSF9xRlJkc3FaUlZ0Y3E3WVktMFZVS2lCendWc1IzdkZUamdCUjl5NWZrNWRjN2tiU19JZEU5NjhHei1GbEVIdW1FYzVybXV3c1VCOGwydGM?oc=5","date":"2026-03-25","type":"pipeline","source":"AASTOCKS.com","summary":"Jefferies Raises TP for CSPC Pharmaceutical Group (01093.HK) to HKD7.2, Maintains 'Underperform' Rating - AASTOCKS.com","headline":"Jefferies Raises TP for CSPC Pharmaceutical Group (01093.HK) to HKD7.2, Maintains 'Underperform' Rating","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-06","type":"trial","source":"simplywall.st","summary":"Emcure Pharmaceuticals Limited's (NSE:EMCURE) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - simplywall.st","headline":"Emcure Pharmaceuticals Limited's (NSE:EMCURE) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Fin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOVVI3VVlMTkdqcE5UR1ZGQzVIYkRrUnpkZW00akZBMDkyMUxSSHhpNmNUTkFKdnFkalZubEdLSm9TNFVrdDd5dzZYZ3FEWFcySXctLWFTTVVNVF94MkRuS2hCYkNJLWJxV2xORFkzVmNwbzByU1BxRDMteVVkRkFRSnVVOTVIa1dIcUFNd1o5VTNtVDB1Vnd2eV8tMWZCaEdWV3NnbXBNaENRdmxtSjN6UEN3?oc=5","date":"2025-12-04","type":"pipeline","source":"USA Today","summary":"I sold Big Pharma's agenda. Cancer changed my perspective. | Opinion - USA Today","headline":"I sold Big Pharma's agenda. Cancer changed my perspective. | Opinion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-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?oc=5","date":"2025-12-03","type":"earnings","source":"simplywall.st","summary":"Sun Pharma Advanced Research Company Limited (NSE:SPARC) surges 21%; private companies who own 46% shares profited along with insiders - simplywall.st","headline":"Sun Pharma Advanced Research Company Limited (NSE:SPARC) surges 21%; private companies who own 46% shares profited along","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQRkxHQndtV3RMVUxBSlp0eFRaSTV2NHdVOXhfajRhNFRXT3B4cmV1RkZ0Vm01U1Q2S0p0REZoNnUyUXkwOHJNdXJKQmluLUhldVMxWlVzRk9SU1BNSEUyVWs1enFFTmJvZE1QUl92UlFpeW4yTFB3SzZlSlpjM1VLcnlHMHN3a3VvZVcxNTNlaw?oc=5","date":"2025-07-16","type":"pipeline","source":"PwC","summary":"Medical cost trend: Behind the numbers 2026 - PwC","headline":"Medical cost trend: Behind the numbers 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxObVRrNllHZ1l1eXhjWDFhenozZnA2NFpBQ3M4VmtRdi15ejd2WGVsYXl6aXhldzROcmVQNXZEdVVTXzc4R3Z1azltWXZpWmoySkpVbDNpYWt0ZzdCcUVZNFNzSHd2M1N5RDhhMGM5YnllMW1LQXRGRGZQc21IWkYta2dsZWtSdDh1X0RicWFwbXI4ejNBTV9Ldy1qTFJBWUdfZDI0ejlnb1czRkFQSEVjWHRQYXA?oc=5","date":"2025-06-24","type":"pipeline","source":"LMU Klinikum","summary":"Primary surgery: advantage in ovarian cancer - LMU Klinikum","headline":"Primary surgery: advantage in ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNVFhxakw0OXFiRjJqZjB0N0dyMHNHbWRkZ3BvRlhnSHJnT1FzdnZSclU2OTBzQ1d3UlNxa0owMm5EdlJEbW5oeENHVUd1ajdOZTRzTzFQbnJZTjJtSV9oalhTaGsyakNINWFVaHlZX0RHWkhVWlNkTG9vaFdPSGkwU0FEdWd6LXhtdVBBdWtzWlBLXy14bGwzbDc5ZlZ2SmgxMVQ0QkxqMjNfR0pzUE02b3BHSHpyVlE?oc=5","date":"2025-01-07","type":"trial","source":"phrma.org","summary":"New study: Entities that don’t make medicines get half of what is spent on those medicines - phrma.org","headline":"New study: Entities that don’t make medicines get half of what is spent on those medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE42UzJQcFY0Q3lLYnhkNWZFY00zVHE5cXV3MlZhWWY2WElnWGFvYU1FblNVb09YN0k0ajFwZk1nYVBXUnA0eXdNODh0Vmk4emNaR1RRdE5TSXpwYUNjUWt2SWdvWVdvV1JBQVQwbkdpUjU4d05FcFdV?oc=5","date":"2024-03-26","type":"pipeline","source":"AAMC","summary":"Why we know so little about women’s health - AAMC","headline":"Why we know so little about women’s health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1vbGQ1RHl6R3h0RVY3WnRvQVVHNXJfQmNhYU1VR3ZXSnhIb291VGFLVHUtNDI1TG1Ga1ZuZ1lQV1RxMVBTV0xIREVtQ09jY0dkWmlMdFl6V3NZVlh3Vm96akRYVzByTkk?oc=5","date":"2023-07-11","type":"earnings","source":"Harvard Business School","summary":"Big Pharma has a Model to Make a Profit and Save Lives. So, What’s the Holdup? - Harvard Business School","headline":"Big Pharma has a Model to Make a Profit and Save Lives. So, What’s the Holdup?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQczNyVFJmMWR2S19fWm9mY1AzQzY1VTY3cDkySW0zSjZPOUV6WElzU1gyYWpaLWUtUldpekR1YWZfUjFxSjk0cm9fblhMdEM0TnI4cHpKdkg2VEtaWjVaRmVDZnhsR1ZBTUpMalJGWEZsSkljSzRoU1pZeEtGdF9ZRzdYa01DZDRPWGJSYm9HZmhFMUtnTG5QdjBzcWpfU0tsYkxTVFBDR1VGcGJLOG1YUThDWjlxU0k?oc=5","date":"2021-07-25","type":"trial","source":"The ASCO Post","summary":"Bevacizumab in Advanced Ovarian Cancer: Phase III Trial Finds More Is Not Better - The ASCO Post","headline":"Bevacizumab in Advanced Ovarian Cancer: Phase III Trial Finds More Is Not Better","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBaSmtudllPTWlXTWQ5RERMLVJYVVRVWkN4RTBjd2pGdFBpbF8xNm40RGtxMUhoOERKZmpraFF3eE9hNDZuaHVLbnBvd3NfU01UbHE5QWszelhOYzFENENzQw?oc=5","date":"2019-02-27","type":"trial","source":"NEJM","summary":"A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms - NEJM","headline":"A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":2,"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}